

ASX RELEASE

25 July 2022

## PRESENTATION AT MAJOR PANCREATIC CANCER CONFERENCE

- *Amplia to present AMP945 clinical trial at major international pancreatic cancer conference in Boston, MA.*

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a company developing new approaches for the treatment of cancer and fibrosis, is pleased to announce that an abstract describing the Company’s ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer has been accepted for presentation at the **American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer**, being held from September 13-16 in Boston, MA.

The presentation will be entitled “*Rationale for the use of pulsed rather than continual dosing of the novel Focal Adhesion Kinase inhibitor AMP945 in pancreatic cancer*” and will describe the scientific rationale and clinical trial design for ACCENT. The trial is currently open for recruitment and has been registered on ClinicalTrials.gov with an identifier number of NCT05355298.

“The AACR special topic meetings attract the world’s leading cancer researchers who are working at the cutting edge of cancer research and new drug development. We’re delighted to have Amplia’s work accepted for presentation in this forum and expect it will raise awareness in the global clinical community of AMP945 and its potential in this devastating cancer.”

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

### For Further Information

Dr. John Lambert  
CEO and Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

### About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).